Global anti-diabetic revenue by top ten pharmaceutical companies 2017 and 2024

The top pharmaceutical companies based on global anti-diabetic revenue include big-name pharmaceutical leaders such as Novo Nordisk and Eli Lilly. As of 2017, Novo Nordisk was the top global anti-diabetic revenue generator with over 13.7 billion U.S. dollars in revenue for that year. Novo Nordisk is projected to continue being the top anti-diabetic pharmaceutical company by 2024. They are projected to make about 21 billion U.S. dollars in anti-diabetic pharmaceuticals revenue in the year 2024.

Diabetes treatments and prevalence

Diabetes is a chronic illness caused by the pancreas not producing enough insulin or the body not effectively using insulin. The global prevalence of diabetes in 2017 was about 8.8 percent and that is expected to increase significantly by 2045. Though not all countries are affected equally. Many Pacific Island nations have a significantly higher prevalence of diabetes than the rest of the world. Likewise, not all countries have the same standards of care or costs for care. Norway, Switzerland and the U.S. have the some of the highest costs per person with diabetes as of 2017.

Top diabetes pharmaceuticals

There are many types of treatments for diabetes. As of 2017, Novo Nordisk’s NovoRapid insulin held the highest share among all anti-diabetic products on the market. NovoRapid is primarily used in the treatment of type I diabetes. Other types of insulin are also among the top anti-diabetic products. When based on revenue generated, the top anti-diabetic products included Eli Lilly’s Trulicity and Boehringer Ingelheim’s Jardiance, medications used primarily in the treatment of type 2 diabetes.